Drug profile

The FDA adverse-event record for Rabies Equine Havlogen Adj Kv

11 FDA reports name Rabies Equine Havlogen Adj Kv, a lower-volume drug in the CVM extract. Species, reactions, and outcomes follow.

#2498 of 2,679
by report volume (all drugs)
11
adverse-event reports
27.3%
death-coded share
Horse
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Rabies Equine Havlogen Adj Kv ranks #2412 of 2679 by total reports (11). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#2412
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Rabies Equine Havlogen Adj Kv has 11 reports now versus 10 in that prior snapshot: 1 more (10.0%).

Report change
+1
Death-coded reports
+1
Death-coded share
+7.3 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Rabies Equine Havlogen Adj Kv changes

Signature read: 11 reports place Rabies Equine Havlogen Adj Kv in the lower third of FDA AER volume (#2498 of 2,679).

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
11
Total Reports
3
Deaths Reported
27.3%
Death-coded share of reports

Active Ingredients

Rabies Equine Havlogen Adj Kv

Administration Routes

IntramuscularUnknown

Species Affected

Horse 11

Most Affected Breeds

Warmblood (unspecified) 3
Miniature 2
Crossbred Equine/horse 2
Thoroughbred 1
Warmblood - Dutch 1
Oldenburg 1
Appaloosa 1

Most Reported Reactions

Fever 4
Colic 4
Abdominal discomfort 2
Not eating 2
Shaking 2
Pawing 2
Gut sounds decreased 2
Death 2
Seizure NOS 2
Lying down 2
Anaphylaxis 2
Injection site pain 1

Outcome Breakdown

Recovered/Normal
6 (54.5%)
Ongoing
2 (18.2%)
Died
2 (18.2%)
Euthanized
1 (9.1%)

Rabies Equine Havlogen Adj Kv: high death-coded share in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Rabies Equine Havlogen Adj Kv (#2498 of 2,679 by report volume); death-coded 27.3%. PlainBreed drug row · report volume stamp 11 · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →